Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 10, 2025

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

8.5K

Garadacimab: First Approval.

Simon Fung1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|April 22, 2025
PubMed
Summary
This summary is machine-generated.

Garadacimab is a new monoclonal antibody for preventing hereditary angioedema attacks. It has received first approvals in Australia and the UK for patients aged 12 and older.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

97
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
97

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deuruxolitinib: New Approval.

Clinical drug investigation·2026
Same author

Bevifibatide: First Approval.

Drugs·2026
Same author

Remibrutinib: First Approval.

Drugs·2026
Same author

Correction: Ifupinostat: First Approval.

Drugs·2026
Same author

Ifupinostat: First Approval.

Drugs·2025
Same author

Fosrolapitant/Palonosetron: First Approval.

Drugs·2025
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Immunology
  • Pharmacology

Background:

  • Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent, unpredictable swelling attacks.
  • Current treatments aim to manage acute attacks, but prophylactic options are crucial for improving patient quality of life.

Purpose of the Study:

  • To summarize the key development milestones of garadacimab.
  • To highlight the regulatory approvals for garadacimab in HAE prevention.

Main Methods:

  • Garadacimab is a fully human monoclonal antibody targeting activated Factor XII (FXIIa).
  • Development involved preclinical studies and clinical trials assessing safety and efficacy in HAE patients.

Main Results:

  • Garadacimab received first approvals in Australia and the UK in January 2025 for HAE prevention in patients aged 12 years and older.

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

924
Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood
09:29

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

18.3K

Related Experiment Videos

Last Updated: May 10, 2025

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

8.5K
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

924
Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood
09:29

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

18.3K
  • Subsequent approvals were granted in the EU, Japan, and Switzerland in February 2025.
  • Regulatory reviews are ongoing in the USA and Canada.

    • Conclusions:

    • Garadacimab represents a significant advancement in HAE prophylaxis.
    • The drug's development milestones and recent approvals mark a new era for HAE management.